APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Distress Syndrome

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

Selected research

Industry Growth & Trends

Global Respiratory Distress Syndrome Industry Growth and Trends Forecast to 2032

19 December 202589 pages

Choose your research edition.

Industry ResearchRespiratory Distress Syndrome Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Distress Syndrome Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Respiratory Distress Syndrome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Distress Syndrome Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Distress Syndrome Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

According to APO Research, the global Respiratory Distress Syndrome market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Respiratory Distress Syndrome market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Respiratory Distress Syndrome market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Respiratory Distress Syndrome market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Respiratory Distress Syndrome.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Respiratory Distress Syndrome market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Respiratory Distress Syndrome Market by Company

Chiesi Farmaceutici

CR-Double Crane

ONY Biotech

AbbVie

Yuhan Corporation

JW Pharmaceuticals

Noargen

Respiratory Distress Syndrome Segment by Type

Poractant Alfa

Beractant

Calfactant

Others

Respiratory Distress Syndrome Segment by Application

Very Preterm Infants

Moderate to Late Preterm Infants

Others

Respiratory Distress Syndrome Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Distress Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Distress Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Distress Syndrome.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Respiratory Distress Syndrome companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Respiratory Distress Syndrome Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Respiratory Distress Syndrome Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Respiratory Distress Syndrome Market Share by Region (2021-2026) Table 4. Global Respiratory Distress Syndrome Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Respiratory Distress Syndrome Market Share by Region (2027-2032) Table 6. Global Respiratory Distress Syndrome Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Respiratory Distress Syndrome Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Respiratory Distress Syndrome Market Size Share by Type (2021-2026) Table 9. Global Respiratory Distress Syndrome Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Respiratory Distress Syndrome Market Size Share Forecasted by Type (2027-2032) Table 11. North America Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Respiratory Distress Syndrome Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Respiratory Distress Syndrome Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Respiratory Distress Syndrome Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Respiratory Distress Syndrome Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Respiratory Distress Syndrome Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Respiratory Distress Syndrome Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Respiratory Distress Syndrome Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Respiratory Distress Syndrome Market Size Share by Application (2021-2026) Table 24. Global Respiratory Distress Syndrome Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Respiratory Distress Syndrome Market Size Share Forecasted by Application (2027-2032) Table 26. North America Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Respiratory Distress Syndrome Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Respiratory Distress Syndrome Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Respiratory Distress Syndrome Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Respiratory Distress Syndrome Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Respiratory Distress Syndrome Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Respiratory Distress Syndrome Industry Trends Table 37. Respiratory Distress Syndrome Industry Drivers Table 38. Respiratory Distress Syndrome Industry Opportunities and Challenges Table 39. Respiratory Distress Syndrome Industry Restraints Table 40. Global Respiratory Distress Syndrome Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Respiratory Distress Syndrome Revenue Market Share by Company (2021-2026) Table 42. Global Respiratory Distress Syndrome Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Respiratory Distress Syndrome Key Company Headquarters & Area Served Table 44. Global Respiratory Distress Syndrome Company, Product Type & Application Table 45. Global Respiratory Distress Syndrome Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Respiratory Distress Syndrome by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Chiesi Farmaceutici Company Information Table 49. Chiesi Farmaceutici Business Overview Table 50. Chiesi Farmaceutici Respiratory Distress Syndrome Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Chiesi Farmaceutici Respiratory Distress Syndrome Product Portfolio Table 52. Chiesi Farmaceutici Recent Development Table 53. CR-Double Crane Company Information Table 54. CR-Double Crane Business Overview Table 55. CR-Double Crane Respiratory Distress Syndrome Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. CR-Double Crane Respiratory Distress Syndrome Product Portfolio Table 57. CR-Double Crane Recent Development Table 58. ONY Biotech Company Information Table 59. ONY Biotech Business Overview Table 60. ONY Biotech Respiratory Distress Syndrome Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. ONY Biotech Respiratory Distress Syndrome Product Portfolio Table 62. ONY Biotech Recent Development Table 63. AbbVie Company Information Table 64. AbbVie Business Overview Table 65. AbbVie Respiratory Distress Syndrome Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. AbbVie Respiratory Distress Syndrome Product Portfolio Table 67. AbbVie Recent Development Table 68. Yuhan Corporation Company Information Table 69. Yuhan Corporation Business Overview Table 70. Yuhan Corporation Respiratory Distress Syndrome Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Yuhan Corporation Respiratory Distress Syndrome Product Portfolio Table 72. Yuhan Corporation Recent Development Table 73. JW Pharmaceuticals Company Information Table 74. JW Pharmaceuticals Business Overview Table 75. JW Pharmaceuticals Respiratory Distress Syndrome Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. JW Pharmaceuticals Respiratory Distress Syndrome Product Portfolio Table 77. JW Pharmaceuticals Recent Development Table 78. Noargen Company Information Table 79. Noargen Business Overview Table 80. Noargen Respiratory Distress Syndrome Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Noargen Respiratory Distress Syndrome Product Portfolio Table 82. Noargen Recent Development Table 83. North America Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 84. North America Respiratory Distress Syndrome Market Size by Country (2021-2026) & (US$ Million) Table 85. North America Respiratory Distress Syndrome Market Share by Country (2021-2026) Table 86. North America Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032) & (US$ Million) Table 87. North America Respiratory Distress Syndrome Market Share Forecast by Country (2027-2032) Table 88. Europe Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. Europe Respiratory Distress Syndrome Market Size by Country (2021-2026) & (US$ Million) Table 90. Europe Respiratory Distress Syndrome Market Share by Country (2021-2026) Table 91. Europe Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. Europe Respiratory Distress Syndrome Market Share Forecast by Country (2027-2032) Table 93. Asia-Pacific Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. Asia-Pacific Respiratory Distress Syndrome Market Size by Country (2021-2026) & (US$ Million) Table 95. Asia-Pacific Respiratory Distress Syndrome Market Share by Country (2021-2026) Table 96. Asia-Pacific Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. Asia-Pacific Respiratory Distress Syndrome Market Share Forecast by Country (2027-2032) Table 98. Latin America Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Latin America Respiratory Distress Syndrome Market Size by Country (2021-2026) & (US$ Million) Table 100. Latin America Respiratory Distress Syndrome Market Share by Country (2021-2026) Table 101. Latin America Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Latin America Respiratory Distress Syndrome Market Share Forecast by Country (2027-2032) Table 103. Middle East & Africa Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Middle East & Africa Respiratory Distress Syndrome Market Size by Country (2021-2026) & (US$ Million) Table 105. Middle East & Africa Respiratory Distress Syndrome Market Share by Country (2021-2026) Table 106. Middle East & Africa Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Middle East & Africa Respiratory Distress Syndrome Market Share Forecast by Country (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Respiratory Distress Syndrome Product Image Figure 3. Global Respiratory Distress Syndrome Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Respiratory Distress Syndrome Market Size (2021-2032) & (US$ Million) Figure 5. Global Respiratory Distress Syndrome Market Share by Region: 2025 VS 2032 Figure 6. Global Respiratory Distress Syndrome Market Share by Region (2021-2032) Figure 7. North America Respiratory Distress Syndrome Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Respiratory Distress Syndrome Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Respiratory Distress Syndrome Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Respiratory Distress Syndrome Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Respiratory Distress Syndrome Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Poractant Alfa Image Figure 13. Global Poractant Alfa Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Beractant Image Figure 15. Global Beractant Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Calfactant Image Figure 17. Global Calfactant Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Others Image Figure 19. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Respiratory Distress Syndrome Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Respiratory Distress Syndrome Market Share by Type 2025 VS 2032 Figure 22. North America Respiratory Distress Syndrome Market Size Share by Type (2021-2032) Figure 23. Europe Respiratory Distress Syndrome Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Respiratory Distress Syndrome Market Size Share by Type (2021-2032) Figure 25. Latin America Respiratory Distress Syndrome Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Respiratory Distress Syndrome Market Size Share by Type (2021-2032) Figure 27. Very Preterm Infants Image Figure 28. Global Very Preterm Infants Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Moderate to Late Preterm Infants Image Figure 30. Global Moderate to Late Preterm Infants Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Others Image Figure 32. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Respiratory Distress Syndrome Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Respiratory Distress Syndrome Market Share by Application 2025 VS 2032 Figure 35. North America Respiratory Distress Syndrome Market Size Share by Application (2021-2032) Figure 36. Europe Respiratory Distress Syndrome Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Respiratory Distress Syndrome Market Size Share by Application (2021-2032) Figure 38. Latin America Respiratory Distress Syndrome Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Respiratory Distress Syndrome Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Respiratory Distress Syndrome Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Respiratory Distress Syndrome Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Respiratory Distress Syndrome Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Respiratory Distress Syndrome Market Share by Country (2021-2032) Figure 45. Europe Respiratory Distress Syndrome Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Respiratory Distress Syndrome Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Respiratory Distress Syndrome Market Share by Country (2021-2032) Figure 48. Asia-Pacific Respiratory Distress Syndrome Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Respiratory Distress Syndrome Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Respiratory Distress Syndrome Market Share by Country (2021-2032) Figure 51. Latin America Respiratory Distress Syndrome Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Respiratory Distress Syndrome Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Respiratory Distress Syndrome Market Share by Country (2021-2032) Figure 54. Middle East & Africa Respiratory Distress Syndrome Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Respiratory Distress Syndrome Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Respiratory Distress Syndrome Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Poractant Alfa
  • Beractant
  • Calfactant
  • Others
Applications
  • Very Preterm Infants
  • Moderate to Late Preterm Infants
  • Others
Companies covered
  • Chiesi Farmaceutici
  • CR-Double Crane
  • ONY Biotech
  • AbbVie
  • Yuhan Corporation
  • JW Pharmaceuticals
  • Noargen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Respiratory Distress Syndrome Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Respiratory Distress Syndrome Market Size by Region (2021-2032)
  5. 1.4.1 Global Respiratory Distress Syndrome Market Size by Region (2021-2026)
  6. 1.4.2 Global Respiratory Distress Syndrome Market Size by Region (2027-2032)
  7. 1.5 Key Regions Respiratory Distress Syndrome Market Size (2021-2032)
  8. 1.5.1 North America Respiratory Distress Syndrome Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Respiratory Distress Syndrome Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Respiratory Distress Syndrome Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Respiratory Distress Syndrome Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Respiratory Distress Syndrome Market Size Growth Rate (2021-2032)
2 Respiratory Distress Syndrome Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Poractant Alfa
  3. 2.1.2 Beractant
  4. 2.1.3 Calfactant
  5. 2.1.4 Others
  6. 2.2 Global Respiratory Distress Syndrome Market Size by Type
  7. 2.2.1 Global Respiratory Distress Syndrome Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Respiratory Distress Syndrome Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Respiratory Distress Syndrome Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Respiratory Distress Syndrome Market Size by Regions
  11. 2.3.1 North America Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Respiratory Distress Syndrome Market Size Breakdown by Type (2021-2026)
3 Respiratory Distress Syndrome Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Very Preterm Infants
  3. 3.1.2 Moderate to Late Preterm Infants
  4. 3.1.3 Others
  5. 3.2 Global Respiratory Distress Syndrome Market Size by Application
  6. 3.2.1 Global Respiratory Distress Syndrome Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Respiratory Distress Syndrome Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Respiratory Distress Syndrome Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Respiratory Distress Syndrome Market Size by Regions
  10. 3.3.1 North America Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Respiratory Distress Syndrome Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Respiratory Distress Syndrome Industry Trends
  2. 4.2 Respiratory Distress Syndrome Industry Drivers
  3. 4.3 Respiratory Distress Syndrome Industry Opportunities and Challenges
  4. 4.4 Respiratory Distress Syndrome Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Respiratory Distress Syndrome Revenue (2021-2026)
  2. 5.2 Global Respiratory Distress Syndrome Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Respiratory Distress Syndrome Key Company Headquarters & Area Served
  4. 5.4 Global Respiratory Distress Syndrome Company, Product Type & Application
  5. 5.5 Global Respiratory Distress Syndrome Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Respiratory Distress Syndrome Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Respiratory Distress Syndrome Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Respiratory Distress Syndrome Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Chiesi Farmaceutici
  2. 6.1.1 Chiesi Farmaceutici Company Information
  3. 6.1.2 Chiesi Farmaceutici Business Overview
  4. 6.1.3 Chiesi Farmaceutici Respiratory Distress Syndrome Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Chiesi Farmaceutici Respiratory Distress Syndrome Product Portfolio
  6. 6.1.5 Chiesi Farmaceutici Recent Developments
  7. 6.2 CR-Double Crane
  8. 6.2.1 CR-Double Crane Company Information
  9. 6.2.2 CR-Double Crane Business Overview
  10. 6.2.3 CR-Double Crane Respiratory Distress Syndrome Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 CR-Double Crane Respiratory Distress Syndrome Product Portfolio
  12. 6.2.5 CR-Double Crane Recent Developments
  13. 6.3 ONY Biotech
  14. 6.3.1 ONY Biotech Company Information
  15. 6.3.2 ONY Biotech Business Overview
  16. 6.3.3 ONY Biotech Respiratory Distress Syndrome Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 ONY Biotech Respiratory Distress Syndrome Product Portfolio
  18. 6.3.5 ONY Biotech Recent Developments
  19. 6.4 AbbVie
  20. 6.4.1 AbbVie Company Information
  21. 6.4.2 AbbVie Business Overview
  22. 6.4.3 AbbVie Respiratory Distress Syndrome Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 AbbVie Respiratory Distress Syndrome Product Portfolio
  24. 6.4.5 AbbVie Recent Developments
  25. 6.5 Yuhan Corporation
  26. 6.5.1 Yuhan Corporation Company Information
  27. 6.5.2 Yuhan Corporation Business Overview
  28. 6.5.3 Yuhan Corporation Respiratory Distress Syndrome Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Yuhan Corporation Respiratory Distress Syndrome Product Portfolio
  30. 6.5.5 Yuhan Corporation Recent Developments
  31. 6.6 JW Pharmaceuticals
  32. 6.6.1 JW Pharmaceuticals Company Information
  33. 6.6.2 JW Pharmaceuticals Business Overview
  34. 6.6.3 JW Pharmaceuticals Respiratory Distress Syndrome Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 JW Pharmaceuticals Respiratory Distress Syndrome Product Portfolio
  36. 6.6.5 JW Pharmaceuticals Recent Developments
  37. 6.7 Noargen
  38. 6.7.1 Noargen Company Information
  39. 6.7.2 Noargen Business Overview
  40. 6.7.3 Noargen Respiratory Distress Syndrome Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Noargen Respiratory Distress Syndrome Product Portfolio
  42. 6.7.5 Noargen Recent Developments
7 North America
  1. 7.1 North America Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Respiratory Distress Syndrome Market Size by Country (2021-2026)
  3. 7.3 North America Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Respiratory Distress Syndrome Market Size by Country (2021-2026)
  3. 8.3 Europe Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Respiratory Distress Syndrome Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Respiratory Distress Syndrome Market Size by Country (2021-2026)
  3. 10.3 South America Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Respiratory Distress Syndrome Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Respiratory Distress Syndrome Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst